Washington Trust Introduces New Home Equity Line of Credit
Limited time promotion offers a low fixed rate for an 18-month intro period
"Home Equity Lines of Credit are a smart way to have funds available when you need them," said Rolando A. Lora, EVP, Chief Retail Lending Officer and Director of Community Lending at Washington Trust. "The flexibility of this product, along with a low initial rate locked in for a full 18 months, is a great way to make home improvements now, that you can enjoy for years to come."
The special promotion is available for a limited time. Applications can be made by visiting any Washington branch location, calling the bank at 800-475-2265, or applying quickly and easily online for an answer in less than a minute.
To learn more about Home Equity Lines of Credit, or for more details on the 5.99% APR offer, visit washtrust.com/HELOC.
Additional information
*Introductory Annual Percentage Rate (APR) of 5.99% is fixed for the first 18 months. Your actual (APR) may be different than the rates shown. APR is based on the specific characteristics of your credit application including but not limited to: evaluation of credit history, amount of credit requested, property type, lien position, and combined loan to value. Offer available for new lines only. All loans subject to credit and underwriting approval. After the introductory rate, the APR is a variable rate based on the Wall Street Journal Prime Rate (minus) -0.125% to (plus) +0.25%, and will not exceed 18.00% or be less than 2.75%. As of 12/19/2024, Prime Rate is 7.50%. Minimum line amount for Prime (minus) -0.125% is
ABOUT WASHINGTON TRUST®
Founded in 1800, Washington Trust is recognized as the oldest community bank in the nation, the largest state-chartered bank headquartered in
View original content to download multimedia:https://www.prnewswire.com/news-releases/washington-trust-introduces-new-home-equity-line-of-credit-302445027.html
SOURCE The Washington Trust Company
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- PwC US and PwC India Form Joint Venture to Help Clients Grow and Compete at Greater Speed and Scale
- Ivonescimab Versus Pembrolizumab in First-Line PD-L1-Positive NSCLC: Positive Overall Survival Results from HARMONi-2 Presented at WCLC 2026
- Apeing Presale Surpasses $80,000 as Stage 3 Progresses Toward Scheduled Stage 4 Launch
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesRelated Entities
FDICSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share